Therapeutic uses for mesenchymal stromal cells
OwnerGihan Tennekoon, Andrew Coyle +2inventors
InventorsGihan Tennekoon, Andrew Coyle, Judith Grinspan, Jackie Beesley
Life of this patent
Estimating the term…
Abstract
Human mesenchymal stromal cells can be induced to differentiate into oligodendrocytes and neurons, respectively. For these cell types, therefore, MSCs can be a therapeutic source, either in vitro or in vivo, in the context of treating pathologies of the central nervous system which are characterized by neuron loss, such as Parkinson's disease, Alzheimer's disease and stroke, as well as head trauma, or by dysfunction in ganglioside storage or demyelinization, such as Tay-Sachs disease, G1 gangliosidosis, metachromatic leukodystrophy, and multiple sclerosis.
Claims21
1-14. (canceled)
A method for treating a pathology characterized by damaged myelin or neurological deterioration, comprising
- (i) providing a composition in vitro that consists essentially of mesenchymal stromal cells and a physiologically compatible carrier,
- (ii) exposing said composition to conditions such that said mesenchymal stromal cells differentiate into differentiated cells selected from the group consisting of neurons and oligodendrocytes, and
- (iii) allowing said differentiated cells to compensate for said neurological deterioration or damaged myelin in a subject suffering from said pathology.
A method for preparing differentiated cells, comprising
- (i) providing a composition that consists essentially of mesenchymal stromal cells and a physiologically compatible carrier and
- (ii) exposing said composition to conditions such that said mesenchymal stromal cells differentiate in vitro into neurons.
A composition that consists essentially of immortalized mesenchymal stromal cells and a physiologically compatible carrier, wherein said cells comprise one or more exogenous genes and wherein at least one of said exogenous genes is hTERT.
A method for treating a pathology characterized by damaged myelin or neurological deterioration, comprising
- (i) providing a composition in vitro that consists essentially of mesenchymal stromal cells and a physiologically compatible carrier
- (ii) culturing said cells in a medium comprising a neuroblastoma conditioned medium, wherein said culturing step provides oligodendrocyte precursor cells capable of differentiating into oligodendrocytes, and
- (iii) allowing said differentiated cells to compensate for said neurological deterioration or damaged myelin in a subject suffering from said pathology.
Dependencies are inferred from the claim text.